Alterity Therapeutics Limited (ATHE) Key Metrics
ATHE key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · Australian dollarsATHE returns How much profit the business earns on the capital it uses.
ATHE financial health Debt, liquidity and how easily interest is covered.
ATHE efficiency & capital use Working capital cycle and where the cash goes.
ATHE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ATHE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ATHE key metrics in Australian dollars
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −53.8% | −43.2% | −104.5% | −47.4% | −39.0% | −74.6% | −74.2% | −73.3% | −41.6% | −27.4% |
| Return on invested capital (ROIC) | −585.6% | −715.6% | −361.5% | −288.0% | −765.4% | −630.2% | −464.9% | −671.6% | −472.7% | −239.8% |
| Return on assets (ROA) | −49.7% | −37.2% | −82.2% | −40.2% | −34.3% | −65.3% | −60.6% | −61.9% | −37.6% | −25.6% |
| Return on tangible assets | −49.7% | −26.4% | −99.5% | −50.5% | −31.1% | −45.6% | −163.5% | −60.1% | −44.1% | −29.8% |
| Free cash flow margin | — | −210.5% | −313.8% | −511.8% | −242.5% | −399.6% | — | — | — | — |
| Financial health | ||||||||||
| Total debt | A$193,475 | A$155,457 | A$159,045 | A$210,384 | A$117,489 | A$65,649 | A$33,747 | A$0 | A$0 | A$0 |
| Cash & short-term investments | A$37.3M | A$40.7M | A$12.6M | A$15.8M | A$34.8M | A$28.1M | A$9.2M | A$14.4M | A$15.2M | A$21.9M |
| Net debt | −A$37.1M | −A$40.5M | −A$12.5M | −A$15.6M | −A$34.7M | −A$28.0M | −A$9.2M | −A$14.4M | −A$15.2M | −A$21.9M |
| Debt / equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / assets | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | 14.52 | 12.98 | 3.54 | 6.17 | 7.07 | 10.92 | 4.88 | 5.98 | 7.06 | 15.88 |
| Quick ratio | 14.52 | 12.98 | 3.55 | 5.59 | 6.79 | 10.92 | 4.67 | 5.79 | 6.96 | 15.72 |
| Working capital | A$42.7M | A$42.3M | A$13.7M | A$22.7M | A$35.3M | A$30.4M | A$10.5M | A$16.5M | A$16.0M | A$23.7M |
| Invested capital | A$5.6M | A$1.9M | A$1.3M | A$7.2M | A$779,281 | A$2.4M | A$1.4M | A$2.2M | A$836,087 | A$1.8M |
| Tangible asset value | A$42.7M | A$42.4M | A$13.8M | A$22.8M | A$35.5M | A$30.5M | A$3.4M | A$16.6M | A$16.1M | A$23.7M |
| Net current asset value | A$42.5M | A$42.2M | A$13.6M | A$22.5M | A$35.3M | A$30.4M | A$10.5M | A$16.5M | A$16.0M | A$23.7M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 | A$0 |
| Share buybacks (net) | — | — | — | — | — | — | — | A$0 | A$0 | A$0 |
| Capex / revenue | — | 0.0% | 0.1% | 0.2% | 1.7% | 0.2% | 4.1% | 6.5% | 31.0% | 21.1% |
| Capex / depreciation | 194.95 | 0.00 | 0.04 | 0.07 | 1.64 | 0.14 | 0.15 | 0.24 | 2.86 | 1.31 |
| Stock-based compensation / revenue | — | 18.0% | 21.9% | 24.7% | 29.4% | 43.4% | −2.9% | 82.1% | 380.0% | 18.5% |
| R&D / revenue | — | 264.8% | 463.9% | 337.0% | 287.8% | 283.1% | 2,453.6% | 11,961.9% | 3,329.5% | 4,305.5% |
| SG&A / revenue | — | 100.8% | 119.0% | 128.7% | 107.6% | 158.4% | 810.0% | 3,942.1% | 2,199.4% | 2,981.4% |
| Efficiency | ||||||||||
| Days sales outstanding | — | 267.7 | 576.2 | 620.6 | 313.3 | 176.1 | 2,168.7 | 13,421.1 | 5,613.6 | 10,782.6 |
| Days of inventory on hand | — | — | 2,169.1 | 2,670.4 | 801.6 | 287.9 | 1,931.1 | 5,399.3 | 4,173.0 | 4,217.2 |
| Days payables outstanding | 2,676.6 | 1,602.0 | 1,956.3 | 2,785.8 | 2,043.8 | 1,217.9 | 4,298.3 | 18,607.5 | 11,711.8 | 3,223.9 |
| Cash conversion cycle (days) | — | -1,334.3 | 789.0 | 505.3 | -928.9 | -753.9 | -198.5 | 212.8 | -1,925.3 | 11,775.9 |
| Receivables turnover | 0.00 | 1.36 | 0.63 | 0.59 | 1.16 | 2.07 | 0.17 | 0.03 | 0.07 | 0.03 |
| Payables turnover | 0.14 | 0.23 | 0.19 | 0.13 | 0.18 | 0.30 | 0.08 | 0.02 | 0.03 | 0.11 |
| Inventory turnover | — | — | — | 0.14 | 0.46 | 1.27 | 0.19 | 0.07 | 0.09 | 0.09 |
| Asset turnover | 0.00 | 0.17 | 0.17 | 0.11 | 0.14 | 0.19 | 0.02 | 0.01 | 0.01 | 0.00 |
| Average receivables | A$5.8M | A$4.0M | A$6.3M | A$6.7M | A$4.4M | A$2.1M | A$2.4M | A$4.0M | A$3.1M | A$3.9M |
| Average payables | A$828,728 | A$559,706 | A$1.1M | A$2.2M | A$2.0M | A$1.2M | A$1.3M | A$1.5M | A$699,470 | A$188,384 |
| Average inventory | — | — | A$1.3M | A$2.1M | A$800,850 | A$283,943 | A$594,810 | A$439,279 | A$249,223 | A$246,423 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 53.7% | 0.0% | 0.0% | 0.0% |
Computed from ATHE's annual financial statements (latest annual report filed August 28, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Australian dollars; data from EODHD. Averages use the opening and closing balance of each year.
ATHE valuation and financial ratios
Alterity Therapeutics earned a return on equity of −53.8% and a return on invested capital of −585.6% in fiscal 2026. It ended the year with A$0.2 million of debt and A$37.3 million in cash and short-term investments, a net cash position of A$37.1 million.
See the ATHE income statement, the ATHE chart for price history, or the ATHE stock overview for the latest quote and news.
ATHE key metrics FAQ
What is Alterity Therapeutics's return on equity?
Alterity Therapeutics's return on equity (ROE) was −53.8% in fiscal 2026: net income of -A$22.9 million on average shareholders' equity of A$42.6 million.
What is Alterity Therapeutics's ROIC?
Alterity Therapeutics's return on invested capital was −585.6% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Alterity Therapeutics have?
Alterity Therapeutics had total debt of A$0.2 million at the end of fiscal 2026, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Alterity Therapeutics's current ratio?
Alterity Therapeutics's current ratio was 14.52 at the end of fiscal 2026: current assets were 14.52 times current liabilities.